BALANCE IS THE KEY
A unique MOA for patients in need
MOA VIDEO
Gaucher disease is rare lysosomal storage disorder caused by a mutation in the gene that makes an enzyme called glucocerebrosidase. Most patients are eligible for enzyme replacement therapy (ERT), but for those who aren't there was nothing they could do about their condition until Zavesca was introduced. The first-approved substrate reduction therapy (SRT), Zavesca had to explain how it worked.
HCP DETAIL AID
To emphasize its unique oral formulation and its key brand benefit of balance, the Zavesca launch campaigned featured 3 capsules in a formation forming the letter Z. The branding was clear and spacious, which reinforced the ease of taking Zavesca and the relief it would bring to patients living with a disease that caused overcrowding of macrophages and limited their life choices.
SALES FORCE BLUEPRINT
This guide gives sales professionals ideas how to leverage the detail aid during their calls with HCPS. It walks through each page and offers talking points and suggestions on how to initiate and guide conversations.
